Technical Coverage on Biotech Stocks -- Anthera Pharma, RXi Pharma, MiMedx, Sarepta Therapeutics, and Navidea Biopharma

LONDON, May 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), RXi Pharmaceuticals Corporation (NASDAQ: RXII), MiMedx Group Inc. (NASDAQ: MDXG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research report on Anthera Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Anthera%20Pharma&d=18-May-2015&s=ANTH. The US markets on Friday, May 15, 2015, ended on a mixed note as the Dow Jones Industrial Average finished at 18,272.56, up 0.11% and the NASDAQ Composite closed at 5,048.29, down 0.05%. The S&P 500 finished the session 0.08% higher at 2,122.73. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 857.50, up 0.21%, with the index advancing 4.02% in the previous three months. Register for your complimentary reports at the links given below.  

Anthera Pharmaceuticals Inc.'s stock edged 0.80% lower, to close the day at $4.99. The stock recorded a trading volume of 0.40 million shares, below its three months average volume of 1.02 million shares. The company's shares oscillated between $4.85 and $5.25 during the session. Over the last one month and over the past three months, Anthera Pharmaceuticals Inc.'s shares have gained 17.41% and 25.06%, respectively. Furthermore, the stock has rallied 215.82% since the start of this year. The company is trading above its 50-day and 200-day moving averages. Anthera Pharmaceuticals Inc.'s 50-day moving average of $4.62 is above its 200-day moving average of $2.94. Additionally, the stock has a Relative Strength Index (RSI) of 59.81. Sign up and read the free notes on ANTH at:

http://get.Investor-Edge.com/pdf/?c=Anthera%20Pharma&d=18-May-2015&s=ANTH

On Friday, shares in RXi Pharmaceuticals Corp. recorded a trading volume of 0.87 million shares, lower than its three months average volume of 0.95 million shares. The stock ended the day at $0.51, which was 6.57% below its previous day's closing of $0.55, and registered an intraday range of $0.51 and $0.57. RXi Pharmaceuticals Corp.'s shares have declined 11.80% in the previous three trading sessions, 29.38% in the last one month, and 55.09% in the past three months. The company is trading below its 50-day and 200-day moving averages of $0.81 and $1.63, respectively. Furthermore, shares of RXi Pharmaceuticals Corp. have an RSI of 29.86. The complimentary notes on RXII can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=RXi%20Pharma&d=18-May-2015&s=RXII

MiMedx Group Inc.'s stock advanced 0.91% to end Friday's session at $9.99. The stock recorded a trading volume of 0.59 million shares, below its three months average volume of 0.82 million shares. The company's shares fluctuated between $9.80 and $10.09 during the session. Shares of the company traded at a PE ratio of 99.90. MiMedx Group Inc.'s shares have fallen by 1.77% over the last one month. However, the stock has gained 5.60% in the previous three trading sessions and 13.65% in the past three months. The company is trading above its 200-day moving average. MiMedx Group Inc.'s 50-day moving average of $10.09 is above its 200-day moving average of $9.13. Additionally, the stock has an RSI of 52.99. Register for free on Investor-Edge and access the latest research on MDXG at:

http://get.Investor-Edge.com/pdf/?c=MiMedx&d=18-May-2015&s=MDXG

On Friday, shares in Sarepta Therapeutics Inc. fluctuated between $14.96 and $15.45 before ending the session 0.72% lower at $15.21. The stock reported a trading volume of 0.83 million shares, lower than its three months average volume of 0.91 million shares. Sarepta Therapeutics Inc.'s stock has gained 14.88% in the last one month, 3.54% in the previous three months, and 5.11% on YTD basis. The company is trading above its 50-day moving average of $13.81, which is below the 200-day moving average of $16.49. Moreover, shares of Sarepta Therapeutics Inc. have an RSI of 62.34. The complete research on SRPT is available for free at:

http://get.Investor-Edge.com/pdf/?c=Sarepta%20Therapeutics&d=18-May-2015&s=SRPT

Navidea Biopharmaceuticals Inc.'s stock finished Friday's session 1.53% lower at $1.29. A total of 0.43 million shares were traded, which was below its three months average volume of 0.51 million shares. The stock vacillated between $1.28 and $1.32 during the session. The stock has advanced 0.78% in the previous three trading sessions. However, over the last one month and over the past three months, Navidea Biopharmaceuticals Inc.'s shares have lost 12.84% and 22.29%, respectively. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $1.52 is greater than its 200-day moving average of $1.47. Navidea Biopharmaceuticals Inc.'s stock has an RSI of 35.96. Free in depth research on NAVB is available at:

http://get.Investor-Edge.com/pdf/?c=Navidea%20Biopharma&d=18-May-2015&s=NAVB

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge